Omipalisib (GSK2126458)

InformationOmipalisib (GSK2126458, GSK458) is a highly selective and potent inhibitor ofp110α/β/δ/γ, mTORC1/2 withKiof 0.019 nM/0.13 nM/0.024 nM/0.06 nM and 0.18 nM/0.3 nM in cell-free assays, respectively. Omipalisib inducesautophagy. Phase 1.In vitroGSK2126458 potently inhibits the activity of common activating mutants of p110α (E542K, E545K, and H1047R) found in human cancer with Ki of 8 pM, 8 pM and 9 pM, respectively. GSK2126458 causes a significant reduction in the levels of pAkt-S473 with remarkable potency in T47D and BT474 cells with IC50 of 0.41 nM and 0.18 nM, respectively. Furthermore, GSK2126458 leads to a G1 cell cycle arrest and produces the inhibitory effect on cell proliferation in a large panel of cell lines, including T47D and BT474 breast cancer lines with IC50 of 3 nM and 2.4 nM, respectively.In vivoIn a BT474 human tumor xenograft model, GSK2126458 treatment results in a dose-dependent reduction in pAkt-S473 levels, and exhibited dose-dependent tumor growth inhibition at a low dose of 300 μg /kg. Besides, GSK2126458 shows low blood clearance and good oral bioavailability in four preclinical species (mouse, rat, dog, and monkey).Cell Datacell lines：Concentrations：0-1 μMIncubation Time：72 hoursPowder Purity:≥99%. Specification: 10mM in DMSO Molecular Formula: C25H17F2N5O3S Molecular Weight: 505.5